Medical World News Behind the Science
Behind the Science, with host Gina Mauro, provides a comprehensive snapshot of the hottest news of the day and the controversial expert opinions behind them, delivered in a modern man-on-the-street format! Join in to hear the opinions behind the science.
Behind the Science: Behind ACC 2023
During their time conducting on-site interviews on the floor at the American College of Cardiology’s 72nd Annual Scientifc Sessions with Together With the World Congress of Cardiology, HCPLive asked a half dozen expert for their opinion on the single most important piece of data to come from the meeting.
Behind the Science: Behind ASCO Gastrointestinal Cancers Symposium
During the 2023 ASCO Gastrointestinal Cancers Symposium, Targeted Oncology spoke with Dr. Rachna Schroff, David O’Malley, Benjamin Schlechter, Zev Wainberg, Laura Dawson, and more about exciting clinical trials in gastrointestinal cancers.
Behind the Science: Behind Challenges in Cannabis Testing
There are several challenges in cannabis testing, which can make it difficult to ensure accurate and reliable results. Some of these challenges range from regulatory inconsistencies between states and countries, making it difficult to establish consistent testing standards; complex chemistry and subsequent analysis; sample variability; lack of standardized methods; contamination; and limited research. Here, several analytical chemistry experts weigh in on what they believe are the biggest challenges facing the cannabis testing world.
Behind the Science: Behind Drug Development
Real-world data—coming from EMRs, medical insurance claims, prescription data, or any data that can provide insights about patients and their relationship to the healthcare system—is increasingly being used in clinical trials and in drug outcomes measurement to inform processes in the development-to-market chain, which ultimately will improve clinical care for patients. We recently asked these experts, “In your opinion, what is the most exciting use for real-world data in drug development?”
Behind the Science: Behind the Latest in Prostate Cancer
Cases of advanced prostate cancer are increasing for the first time in 20 years, according to new data from the Cancer Statistics, 2023 report released by The American Cancer Society. In this video, urologists Michael S. Cookson, MD, MMHC; Andres Correa, MD; Derek J. Lomas, MD, PharmD; and Jonathan E. Shoag, MD, react to the findings.
Behind the Science: Behind Advances in CAR-T Therapy
At the 64th American Society of Hematology Annual Meeting, the CGTLive team caught up with experts in the clinical care of patients who are receiving cell and gene treatments. A variety of data were presented on the latest advances in CAR-T therapies that are being evaluated for different patient populations. Specifically, they offered insight into the trends they’ve observed in the development of these treatments, the needs that are lingering where progress has been made, and much more.
Behind the Science: Behind Potential of Preventing Seizures in TSC Through Sirolimus
Initiated in October 2021, TSC Steps is a phase 1/2 study that is the first of its kind to evaluate a targeted, disease-modifying therapy for preventing or delaying seizure onset in tuberous sclerosis complex (TSC) using a mechanism based approach. Led by Darcy Krueger, MD, PhD, the study use TAVT-18, a novel formulation of sirolimus (Ramapune; Pfizer), an FDA-approved medication for TSC that aims to regulate the target of rapamycin signaling pathway. This discussion talks about how sirolimus had been previously used and the nuances with treatment decisions.
Behind the Science: Behind Unmet Needs in the Lymphoma Space
We asked a variety of lymphoma experts what unmet needs they still believe must be filled in their respective fields. Oncologists focus on multiple spaces, such as diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, and more. Some answers included the need for more treatment options to help treat patients, to further understand why patients relapse, and move away from using chemotherapy in the front-line setting.
Behind the Science: Behind Breaking the Cycle of Recurrent C Difficile
The healthcare-associated infection, C difficile, can be especially problematic for patients and clinicians. It is estimated that between 15% to 30% of patients who respond to antibiotics experience recurrent C difficile. And a second recurrence rate of 40% can happen to those who have a resolved first recurrence. This subset of patients who get additional recurrences can begin to experience a revolving door of healthcare interactions, diminished quality of life, and severe health consequences. In this video segment, clinicians and stakeholders offer some insights for how a biotherapeutic could help these patients.